News for Cochlear Limited (CHEOY)

**media[651779]**

PR NewswireLONE TREE, Colo., June 2, 2025 NEW Baha® 7 Sound Processor: First in bone conduction to enable Bluetooth® LE Audio* and Auracastâ„¢ broadcast

**media[614516]**

The Australian-developed Minder system is an implantable device for continuous monitoring of brain activity in patients with epilepsy, developed to address the shortcomings in current electroencephalogram technologies The FDA has granted authorisation for Minder under its De Novo pathway creating a new classification of device, allowing for marketing and sale of the device in the US for patients with drug resistant epilepsy Epiminder intends to launch Minder in the US during H2 2025 MELBOURNE, Australia and DALLAS, April 23, 2025 /PRNewswire/ -- Epiminder, a pioneering medical device and information solutions company, today announced that it has been granted FDA authorisation via the De Novo classification for Minder, its proprietary implantable continuous electroencephalogram monitoring system (iCEMTM) for patients with epilepsy. Minder has also been designated as a Breakthrough Technology by the FDA, recognising its potential to provide more effective diagnosis and management for people living with epilepsy. This De Novo authorization is significant as it creates a new classification of device which underscores both the innovation and the clinical validation behind Minder.

PR NewswireLONE TREE, Colo., Feb. 25, 2025 LONE TREE, Colo., Feb. 25, 2025 /PRNewswire/ -- In celebration of International Cochlear Implant Day, Cochlear N

Cochlear Limited (OTCPK:CHEOF) Q2 2025 Earnings Conference Call February 13, 2025 6:00 PM ETCompany ParticipantsDig Howitt - President & Chief Executive...

Cochlear will pay an 8% higher dividend; profits were up 7% for the half year to the end of 2024 despite falling services revenue.

A new day, new Trump tariffs – though this time the U.S.…

**media[528155]**

Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Class A shares outperformed the MSCI ACWI ex-US SMID Index and the Morningstar Foreign Small/Mid Growth peer group average (11.79% for the Fund, 8% for the peer group) for Q3.

Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024

The Bionic Ear Market will grow at a very remarkable rate, mainly due to the increasing prevalence of hearing impairment accompanied by constant...

Citi upgrades Cochlear stock as valuation returns to long-term average

Sensorion Announces Webconference for Retail Shareholders on October 10, 2024

Sensorion Announces the Availability of its Half Year 2024 Report

Sensorion Reports New Positive Clinical Results Presented at the World Congress of Audiology

Sensorion Announces New Positive Clinical Data Across its Gene Therapy and Small Molecule Programs at the World Congress of Audiology in Paris